<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151203</url>
  </required_header>
  <id_info>
    <org_study_id>0409007427</org_study_id>
    <nct_id>NCT00151203</nct_id>
  </id_info>
  <brief_title>Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) for Newly Diagnosed Subjects With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY STUDY OBJECTIVES&#xD;
&#xD;
        -  To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide&#xD;
           (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with&#xD;
           newly diagnosed multiple myeloma (MM).&#xD;
&#xD;
        -  To evaluate the safety of the combination of clarithromycin, lenalidomide, and&#xD;
           dexamethasone as an induction therapy for patients with newly diagnosed MM.&#xD;
&#xD;
      SECONDARY STUDY OBJECTIVES&#xD;
&#xD;
        -  To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone&#xD;
           and lenalidomide.&#xD;
&#xD;
        -  To examine the angiogenesis profile in untreated patients and in patients receiving&#xD;
           induction therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2004</start_date>
  <completion_date type="Actual">September 29, 2020</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate, time to maximum response, toxicities</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin, Lenalidomide, Dexamethasone</intervention_name>
    <description>Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.&#xD;
Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.&#xD;
Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must voluntarily sign and understand written informed consent.&#xD;
&#xD;
          -  Histologically confirmed Durie-Salomon stage II or III MM (see Appendix II). Stage I&#xD;
             MM patients will be eligible if they display poor prognostic factors (ß2M &gt; or = 5.5&#xD;
             mg/L, plasma cell proliferation index &gt; or = 5%, albumin of less then 3.0, and&#xD;
             unfavorable cytogenetics).&#xD;
&#xD;
          -  Measurable disease as defined by &gt; 1.0 g/dL serum monoclonal protein, &gt;0.1 g/dL serum&#xD;
             free light chains, &gt; 0.2 g/24 hrs urinary M-protein excretion, and/or measurable&#xD;
             plasmacytoma(s).&#xD;
&#xD;
          -  Age &gt; or = 18 years at the time of signing the informed consent form.&#xD;
&#xD;
          -  Karnofsky performance status &gt; or = 70% (&gt;60% if due to bony involvement of myeloma&#xD;
             (see Appendix V).&#xD;
&#xD;
          -  No prior treatment or less than one full course of first-line therapy. Patients may be&#xD;
             receiving adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as&#xD;
             routine care.&#xD;
&#xD;
          -  If the patient is a woman of childbearing age, she must have a negative serum or urine&#xD;
             pregnancy test within 7 days of starting study.&#xD;
&#xD;
          -  Due to the unknown risk of teratogenic side effects, subjects (women and men) must&#xD;
             agree to use effective contraception throughout the duration of the study and for at&#xD;
             least 1 month after discontinuation of study drugs.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute neutrophil count (ANC)&gt; or = 1000 cells/mm3 (1.0 x 109/L)&#xD;
&#xD;
          -  Platelets count &gt; or = 75,000/mm3 (75 x 109/L)&#xD;
&#xD;
          -  Serum SGOT/AST &lt; 3.0 x upper limits of normal (ULN)&#xD;
&#xD;
          -  Serum SGPT/ALT &lt; 3.0 x upper limits of normal (ULN)&#xD;
&#xD;
          -  Serum creatinine &lt; 2.5 mg/dL (221 µmol/L)&#xD;
&#xD;
          -  Serum total bilirubin &lt; 2.0 mg/dL (34 µmol/L)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with non-secretory MM (no measurable monoclonal protein, free light chains,&#xD;
             and/or M-spike in blood or urine).&#xD;
&#xD;
          -  Prior history of other malignancies (except for basal cell or squamous cell carcinoma&#xD;
             of the skin or carcinoma in situ of the cervix or breast) unless disease free for ³ 5&#xD;
             years.&#xD;
&#xD;
          -  NYHA Class III or IV heart disease. History of active angina, congestive heart&#xD;
             disease, or myocardial infarction within 6 months.&#xD;
&#xD;
          -  Pregnant or lactating women are ineligible.&#xD;
&#xD;
          -  Known HIV positivity&#xD;
&#xD;
          -  Active viral or bacterial infections or any coexisting medical problem that would&#xD;
             significantly increase the risks of this treatment program.&#xD;
&#xD;
          -  Known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide.&#xD;
&#xD;
          -  Prior therapy for the treatment of MM&#xD;
&#xD;
          -  History of thromboembolic event or other condition currently requiring anticoagulation&#xD;
             with warfarin (Coumadin). Patients whose therapy is changed to heparin are eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Niesvizky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>newly diagnosed multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

